Bixiye
bc-mhcp-pharmprogpolicynotifctn-final-eff-3.1.23.pdf
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1211 - 1220 ee natiijooyinka 3563
Bixiye
QP6-23 Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection
Taariikhda uu dhaqangalayo Barnaamijka: 08, Feb 2023
Bixiye
QP7-23 MHCP Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Lunsumio™, Rebyota™, Sunlenca® Injection, and Vivimusta
Taariikhda uu dhaqangalayo Barnaamijka: 08, Feb 2023
Bixiye
QP8-23 Commercial Formulary Addition for Growth Hormone Therapeutic Class: Genotropin® (somatropin)
Taariikhda uu dhaqangalayo Barnaamijka: 08, Feb 2023
Bixiye
QP9-23 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: 08, Feb 2023
Bixiye
P77R1-22 Update: New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective January 30, 2023
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2023
Bixiye
P6-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Sleep Management Clinical Guideline Updates
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2023
Bixiye
P7-23 Updated Minnesota Health Care Programs (MHCP) and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2023
Bixiye
P55-22 eviCore Healthcare Specialty Utilization Management (UM) Program: Radiation Oncology Clinical Guideline Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2022